FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to a composition for treating colorectal cancer, comprising a therapeutically effective amount of apilimod or a pharmaceutically acceptable salt thereof and at least one additional therapeutic agent, selected from vemurafenib and regorafenib, a composition for treating colorectal cancer in a patient having refractory or metastatic cancer, containing apilimod dimesylate and vemurafenib, compositions for treating colorectal cancer in a patient having a refractory or metastatic cancer, comprising apilimod dimesylate and regorafenib, method of identifying a patient with human colorectal cancer for treating said combinations, a method of treating colorectal cancer, comprising administering a therapeutically effective amount of apilimod or a pharmaceutically acceptable salt thereof, and a method of identifying colorectal cancer as a treatment-sensitive apilimod.
EFFECT: group of inventions widens the range of products for treating colorectal cancer.
19 cl, 24 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APILIMOD COMPOSITION AND METHODS OF USING IT IN TREATING MELANOMA | 2015 |
|
RU2731908C2 |
| APILIMOD FOR USE IN TREATING RENAL CANCER | 2015 |
|
RU2727802C2 |
| METHODS OF TREATING CANCER USING APILIMOD | 2016 |
|
RU2738934C2 |
| COMBINED THERAPY PAC-1 | 2016 |
|
RU2720509C2 |
| COMBINATION THERAPY | 2018 |
|
RU2815400C2 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR | 2017 |
|
RU2774612C2 |
| COMPOUND FOR TREATING CANCER | 2014 |
|
RU2708247C2 |
| METHOD FOR PROLIFERATIVE DISEASE TREATMENT | 2012 |
|
RU2622015C2 |
| BRAF KINASE INHIBITOR N-(3-(5-(4-CHLOROPHENYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-CARBONIL)-2,4-DIFLUOROPHENYL)PROPANE-1-SULFONAMIDE | 2018 |
|
RU2687107C1 |
| N-(3-(5-(4-CHLOROPHENYL)-1N-PYRAZOLO[3,4-B]PYRIDINE-3-CARBONYL)-2,4-DIFLUOROPHENYL)PROPANE-1-SULPHONAMIDE CRYSTALLINE FORM, ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION AND MEDICINE | 2018 |
|
RU2678455C1 |
